In one study, microdosing GLP-1s supported moderate weight loss of up to 10 pounds over 40 weeks in participants. MICRODOSING GLP-1 BENEFITS Do More, Age Less Modulated inflammatory pathways in clinical trials. Studies found a reduced risk of cognitive decline Supported cardiovascular health in clinical trials Improved mitochondrial function and oxidative stress in clinical trials Low doses reduced side effects in clinical trials Supported moderate weight loss of up to 10 pounds over 40 weeks in one study *See studies cited below
Trimethylamine-N-oxide, as a risk factor for atherosclerosis, induces stress in J774A.1 murine macrophages
Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al
The lighter body, improved insulin sensitivity, and reduced inflammation create an optimal foundation for physical performance
You can always go back for seconds
4,18-22,37 Recent meta-analyses of data from the GLP-1RA CVOTs (representing some of the largest and longest-duration studies with these agents), including PIONEER 6, have not identified an increased risk of pancreatitis
